Maarten H Vermeer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5206533/publications.pdf

Version: 2024-02-01

213 papers	15,468 citations	20817 60 h-index	18130 120 g-index
216 all docs	216 docs citations	216 times ranked	7813 citing authors

#	Article	IF	Citations
1	WHO-EORTC classification for cutaneous lymphomas. Blood, 2005, 105, 3768-3785.	1.4	3,529
2	Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood, 2008, 111, 838-845.	1.4	617
3	Primary Cutaneous CD8-Positive Epidermotropic Cytotoxic T Cell Lymphomas. American Journal of Pathology, 1999, 155, 483-492.	3.8	476
4	European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood, 2008, 112, 1600-1609.	1.4	415
5	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology, The, 2018, 19, 1192-1204.	10.7	398
6	EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*. Blood, 2011, 118, 4024-4035.	1.4	365
7	European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/SÃ©zary syndrome â€“ Update 2017. European Journal of Cancer, 2017, 77, 57-74.	2.8	363
8	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and SÃ©zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal of Clinical Oncology, 2015, 33, 3766-3773.	1.6	328
9	The mutational landscape of cutaneous T cell lymphoma and SÃ©zary syndrome. Nature Genetics, 2015, 47, 1465-1470.	21.4	322
10	WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. Journal of Cutaneous Pathology, 2005, 32, 647-674.	1.3	313
11	Reclassification of 300 Primary Cutaneous B-Cell Lymphomas According to the New WHOâ€“EORTC Classification for Cutaneous Lymphomas: Comparison With Previous Classifications and Identification of Prognostic Markers. Journal of Clinical Oncology, 2007, 25, 1581-1587.	1.6	278
12	Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood, 2005, 105, 3671-3678.	1.4	266
13	Epigenetic Profiling of Cutaneous T-Cell Lymphoma: Promoter Hypermethylation of Multiple Tumor Suppressor Genes Including BCL7a, PTPRG, and p73. Journal of Clinical Oncology, 2005, 23, 3886-3896.	1.6	224
14	Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood, 2003, 102, 2213-2219.	1.4	221
15	Oncogenomic analysis of mycosis fungoides reveals major differences with SÃ©zary syndrome. Blood, 2009, 113, 127-136.	1.4	188
16	Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood, 2012, 119, 1643-1649.	1.4	186
17	Novel and Highly Recurrent Chromosomal Alterations in Sézary Syndrome. Cancer Research, 2008, 68, 2689-2698.	0.9	176
18	Primary Cutaneous Marginal Zone B-Cell Lymphoma. Archives of Dermatology, 2005, 141, 1139.	1.4	173

#	Article	IF	Citations
19	Primary Cutaneous Large B-Cell Lymphomas of the Legs. Archives of Dermatology, 1996, 132, 1304.	1.4	167
20	Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. British Journal of Dermatology, 2003, 149, 1183-1191.	1.5	155
21	Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sèzary Syndrome Identified by Gene Expression Analysis. Cancer Research, 2004, 64, 5578-5586.	0.9	155
22	Low-Dose Palliative Radiotherapy for Cutaneous B- and T-Cell Lymphomas. International Journal of Radiation Oncology Biology Physics, 2009, 74, 154-158.	0.8	142
23	Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood, 2007, 109, 1720-1727.	1.4	137
24	bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related.. Journal of Clinical Oncology, 1998, 16, 2080-2085.	1.6	136
25	Most Primary Cutaneous CD30-Positive Lymphoproliferative Disorders Have a CD4-Positive Cytotoxic T-Cell Phenotype. Journal of Investigative Dermatology, 1997, 109, 636-640.	0.7	131
26	MicroRNA expression in SÃ©zary syndrome: identification, function, and diagnostic potential. Blood, 2010, 116, 1105-1113.	1.4	131
27	The PROCLIPI international registry of earlyâ€stage mycosis fungoides identifies substantial diagnostic delay in most patients. British Journal of Dermatology, 2019, 181, 350-357.	1.5	127
28	Array-Based Comparative Genomic Hybridization Analysis Reveals Recurrent Chromosomal Alterations and Prognostic Parameters in Primary Cutaneous Large B-Cell Lymphoma. Journal of Clinical Oncology, 2006, 24, 296-305.	1.6	125
29	Prognostic factors, prognostic indices and staging in mycosis fungoides and SÃ©zary syndrome: where are we now?. British Journal of Dermatology, 2014, 170, 1226-1236.	1.5	121
30	Results of Radiotherapy in 153 Primary Cutaneous B-Cell Lymphomas Classified According to the WHO-EORTC Classification. Archives of Dermatology, 2007, 143, 1520.	1.4	120
31	Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides. JAMA Dermatology, 2016, 152, 992.	4.1	119
32	IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncology, The, 2019, 20, 1160-1170.	10.7	119
33	MicroRNA-21 Expression in CD4+ T Cells Is Regulated by STAT3 and Is Pathologically Involved in SÃ©zary Syndrome. Journal of Investigative Dermatology, 2011, 131, 762-768.	0.7	116
34	Differential Expression of Programmed Death-1 (PD-1) in SÃ©zary Syndrome and Mycosis Fungoides. Archives of Dermatology, 2012, 148, 1379.	1.4	113
35	Functional Dichotomy between Langerhans Cells that Present Antigen to Naive and to Memory/Effector T Lymphocytes. Immunological Reviews, 1990, 117, 159-183.	6.0	111
36	Treatment of Multifocal Primary Cutaneous B-Cell Lymphoma: A Clinical Follow-Up Study of 29 Patients. Journal of Clinical Oncology, 1999, 17, 2471-2471.	1.6	105

#	Article	IF	Citations
37	CD8+ T Cells in Cutaneous T-Cell Lymphoma: Expression of Cytotoxic Proteins, Fas Ligand, and Killing Inhibitory Receptors and Their Relationship With Clinical Behavior. Journal of Clinical Oncology, 2001, 19, 4322-4329.	1.6	105
38	Molecular Cytogenetic Analysis of Chromosomal Breakpoints in the IGH, MYC, BCL6, and MALT1 Gene Loci in Primary Cutaneous B-cell Lymphomas. Journal of Investigative Dermatology, 2004, 123, 213-219.	0.7	105
39	Blood classification and blood response criteria in mycosis fungoidesÂand SÃ©zary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. European Journal of Cancer, 2018, 93, 47-56.	2.8	105
40	Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. British Journal of Dermatology, 2000, 143, 313-319.	1.5	103
41	Ultraviolet B light-induced alterations in epidermal Langerhans cells are mediated in part by tumor necrosis factor-alpha. Photodermatology Photoimmunology and Photomedicine, 1990, 7, 258-65.	1.5	101
42	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Annals of Oncology, 2017, 28, 2517-2525.	1.2	98
43	miRNA expression profiling of mycosis fungoides. Molecular Oncology, 2011, 5, 273-280.	4.6	91
44	Effects of Ultraviolet B Light on Cutaneous Immune Responses of Humans with Deeply Pigmented Skin. Journal of Investigative Dermatology, 1991, 97, 729-734.	0.7	90
45	IgM Expression on Paraffin Sections Distinguishes Primary Cutaneous Large B-cell Lymphoma, Leg Type From Primary Cutaneous Follicle Center Lymphoma. American Journal of Surgical Pathology, 2010, 34, 1043-1048.	3.7	86
46	Fine-Mapping Chromosomal Loss at 9p21: Correlation with Prognosis in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Journal of Investigative Dermatology, 2009, 129, 1149-1155.	0.7	84
47	Expression of Cytotoxic Proteins by Neoplastic T Cells in Mycosis Fungoides Increases with Progression from Plaque Stage to Tumor Stage Disease. American Journal of Pathology, 1999, 154, 1203-1210.	3.8	82
48	The histone deacetylase inhibitors vorinostat and romidepsin downmodulate ILâ€10 expression in cutaneous Tâ€cell lymphoma cells. British Journal of Pharmacology, 2011, 162, 1590-1602.	5.4	78
49	Evaluation of Immunophenotypic and Molecular Biomarkers for SÃ©zary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients. Journal of Investigative Dermatology, 2016, 136, 1364-1372.	0.7	78
50	A Meta-Analysis of Gene Expression Data Identifies a Molecular Signature Characteristic for Tumor-Stage Mycosis Fungoides. Journal of Investigative Dermatology, 2012, 132, 2050-2059.	0.7	75
51	Cucurbitacin I Inhibits Stat3 and Induces Apoptosis in SÃ©zary Cells. Journal of Investigative Dermatology, 2008, 128, 1691-1695.	0.7	74
52	A 2-bp deletion in theGJA1 gene is associated with oculo-dento-digital dysplasia with palmoplantar keratoderma. American Journal of Medical Genetics, Part A, 2005, 132A, 171-174.	1.2	73
53	Oligonucleotide Array-CGH Identifies Genomic Subgroups and Prognostic Markers for Tumor Stage Mycosis Fungoides. Journal of Investigative Dermatology, 2010, 130, 1126-1135.	0.7	71
54	A missense mutation in the type II hair keratin hHb3 is associated with monilethrix. Journal of Medical Genetics, 2005, 42, e19-e19.	3.2	70

#	Article	IF	Citations
55	Cutaneous T cell lymphoma. Nature Reviews Disease Primers, 2021, 7, 61.	30.5	70
56	High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. Blood, 2018, 131, 2086-2089.	1.4	69
57	Epidermal Interferon-Î³ Inducible Protein-10 (IP-10) and Monokine Induced by Î³-Interferon (Mig) but not IL-8 mRNA Expression is Associated with Epidermotropism in Cutaneous T Cell Lymphomas. Journal of Investigative Dermatology, 1998, 111, 222-226.	0.7	67
58	Chromosomal Aberration Patterns Differ in Subtypes of Primary Cutaneous B Cell Lymphomas. Journal of Investigative Dermatology, 2004, 122, 1495-1502.	0.7	67
59	Keratosis Follicularis Spinulosa Decalvans is caused by mutations in MBTPS2. Human Mutation, 2010, 31, 1125-1133.	2.5	67
60	Histopathological and immunophenotypical criteria for the diagnosis of SÃ©zary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 9. British Journal of Dermatology, 2015, 173, 93-105.	1.5	67
61	Cutaneous Anaplastic Large Cell Lymphoma and Peripheral T-Cell Lymphoma NOS Show Distinct Chromosomal Alterations and Differential Expression of Chemokine Receptors and Apoptosis Regulators. Journal of Investigative Dermatology, 2010, 130, 563-575.	0.7	62
62	Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood, 2022, 140, 419-437.	1.4	58
63	High numbers of tumourâ€infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. Journal of Pathology, 2005, 206, 328-336.	4.5	57
64	A genomic and expression study of APâ€1 in primary cutaneous Tâ€cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS. Journal of Cutaneous Pathology, 2008, 35, 899-910.	1.3	57
65	Langerhans cell histiocytosis first presenting in the skin in adults: frequent association with a second haematological malignancy. British Journal of Dermatology, 2012, 167, 1287-1294.	1.5	57
66	Genomic analysis reveals recurrent deletion of JAKâ€STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides. Genes Chromosomes and Cancer, 2018, 57, 653-664.	2.8	56
67	Nuclear Factor-ÎºB Pathwayâ€“Activating Gene Aberrancies in Primary Cutaneous Large B-Cell Lymphoma, Leg Type. Journal of Investigative Dermatology, 2014, 134, 290-292.	0.7	54
68	Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID. Blood, 2006, 107, 4926-4929.	1.4	51
69	Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma. Modern Pathology, 2006, 19, 1270-1276.	5.5	48
70	A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Research, 2002, 62, 5389-92.	0.9	48
71	Primary cutaneous anaplastic large cell lymphoma shows a distinct mi<scp>RNA</scp> expression profile and reveals differences from tumorâ€stage mycosis fungoides. Experimental Dermatology, 2012, 21, 632-634.	2.9	47
72	Epigenomic Analysis of SÃ©zary Syndrome Defines Patterns of Aberrant DNA Methylation and Identifies DiagnosticÂMarkers. Journal of Investigative Dermatology, 2016, 136, 1876-1884.	0.7	46

#	Article	IF	Citations
73	Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: Differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatric Blood and Cancer, 2010, 55, 344-348.	1.5	45
74	Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group. British Journal of Dermatology, 2017, 177, 223-228.	1.5	43
75	Deep-Sequencing Analysis Reveals that the miR-199a2/214 Cluster within DNM3os Represents the Vast Majority of Aberrantly Expressed MicroRNAs in SÃ©zary Syndrome. Journal of Investigative Dermatology, 2012, 132, 1520-1522.	0.7	42
76	Methotrexate-associated B-cell Lymphoproliferative Disorders Presenting in the Skin. American Journal of Surgical Pathology, 2014, 38, 999-1006.	3.7	42
77	High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. American Journal of Surgical Pathology, 2018, 42, 1488-1494.	3.7	42
78	Genetic rearrangements result in altered gene expression and novel fusion transcripts in SÃ©zary syndrome. Oncotarget, 2017, 8, 39627-39639.	1.8	41
79	Treatment of earlyâ€stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*. British Journal of Dermatology, 2021, 184, 722-730.	1.5	39
80	Differential Expression of Thymus and Activation Regulated Chemokine and Its Receptor CCR4 in Nodal and Cutaneous Anaplastic Large-Cell Lymphomas and Hodgkinâ€™s Disease. Modern Pathology, 2002, 15, 838-844.	5.5	38
81	An Integrated Data Resource for Genomic AnalysisÂof Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2018, 138, 2681-2683.	0.7	38
82	Autocrine IL-21 Stimulation Is Involved in the Maintenance of Constitutive STAT3 Activation in SÃ©zary Syndrome. Journal of Investigative Dermatology, 2012, 132, 440-447.	0.7	37
83	Site-Specific Expression of Polycomb-Group Genes Encoding the HPC-HPH/PRC1 Complex in Clinically Defined Primary Nodal and Cutaneous Large B-Cell Lymphomas. American Journal of Pathology, 2004, 164, 533-542.	3.8	35
84	EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood, 2003, 102, 4243-4243.	1.4	34
85	Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 260-266.	2.4	31
86	Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or SÃ©zary Syndrome. Journal of Investigative Dermatology, 2021, 141, 484-495.	0.7	31
87	Cutaneous Gamma/Delta T-cell Lymphoma During Treatment with Etanercept for Rheumatoid Arthritis. Acta Dermato-Venereologica, 2009, 89, 653-654.	1.3	30
88	Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group. British Journal of Dermatology, 2015, 173, 1319-1322.	1.5	30
89	Improved SÃ©zary cell detection and novel insights into immunophenotypic and molecular heterogeneity in SÃ©zary syndrome. Blood, 2021, 138, 2539-2554.	1.4	28
90	Genetic and epigenetic insights into cutaneous T-cell lymphoma. Blood, 2022, 139, 15-33.	1.4	28

#	Article	IF	Citations
91	Ultrastructural studies bearing on the mechanism of UVB-impaired induction of contact hypersensitivity to DNCB in man. Clinical and Experimental Immunology, 2008, 92, 487-493.	2.6	26
92	Acute hemorrhagic edema of infancy (AHEI). Clinics in Dermatology, 2002, 20, 2-3.	1.6	25
93	Acitretin induces capillary leak syndrome inÂaÂpatientÂwith pustular psoriasis. Journal of the American Academy of Dermatology, 2007, 56, 339-342.	1.2	25
94	Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN). Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1957-1971.	2.4	25
95	Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma. American Journal of Surgical Pathology, 2020, 44, 776-781.	3.7	25
96	Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in SÃ©zary syndrome. Blood Cancer Journal, 2020, 10, 57.	6.2	24
97	Exploring the IL-21â€“STAT3 Axis as Therapeutic Target for SÃ©zary Syndrome. Journal of Investigative Dermatology, 2014, 134, 2639-2647.	0.7	23
98	Cardiomyopathy in patients with epidermolysis bullosa simplex with mutations in KLHL24. British Journal of Dermatology, 2018, 179, 1181-1183.	1.5	23
99	Molecular advances in cutaneous T-cell lymphoma. Seminars in Cutaneous Medicine and Surgery, 2018, 37, 81-86.	1.6	22
100	p53 and bcl-2 expression do not correlate with prognosis in primary cutaneous large T-cell lymphomas. Journal of Cutaneous Pathology, 1997, 24, 462-467.	1.3	20
101	Profiling of apoptosis genes identifies distinct types of primary cutaneous large B cell lymphoma. Journal of Pathology, 2008, 215, 340-346.	4.5	20
102	MicroRNA Profiling of Primary Cutaneous Large B-Cell Lymphomas. PLoS ONE, 2013, 8, e82471.	2.5	20
103	Genetic ablation of macrohistone H2A1 leads to increased leanness, glucose tolerance and energy expenditure in mice fed a high-fat diet. International Journal of Obesity, 2015, 39, 331-338.	3.4	20
104	Plaque stage folliculotropic mycosis fungoides: histopathologic features and prognostic factors in a series of 40 patients. Journal of Cutaneous Pathology, 2020, 47, 241-250.	1.3	20
105	Deregulation of JAK2 signaling underlies primary cutaneous CD8⁺ aggressive epidermotropic cytotoxic T-cell lymphoma. Haematologica, 2022, 107, 702-714.	3.5	20
106	Quality of life in patients with Mycosis Fungoides and SÃ©zary Syndrome: a systematic review of the literature. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2377-2387.	2.4	20
107	Accurate Quantification of T Cells by Measuring Loss of Germline T-Cell Receptor Loci with Generic Single Duplex Droplet Digital PCR Assays. Journal of Molecular Diagnostics, 2017, 19, 236-243.	2.8	19
108	Recommendations for the Optimal Radiation Dose in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma: A Report of the Dutch Cutaneous Lymphoma Group. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1279-1285.	0.8	19

#	Article	IF	Citations
109	Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: report of the Dutch Cutaneous Lymphoma Group. British Journal of Dermatology, 2018, 179, 724-731.	1.5	19
110	Is mycosis fungoides exacerbated by fluoxetine?. Journal of the American Academy of Dermatology, 1996, 35, 635-636.	1.2	18
111	NOTCH1 Signaling as a Therapeutic Target in SÃ©zary Syndrome. Journal of Investigative Dermatology, 2012, 132, 2810-2817.	0.7	18
112	A novel mouse model for <scp>S</scp>Ã©zary <scp>S</scp>yndrome using xenotransplantation of <scp>S</scp>Ã©zary cells into immunodeficient <scp>RAG</scp>2^{â¯/â¯} Î³c^{â¯/â¯} mice. Experimental Dermatology, 2012, 21, 706-709.	2.9	18
113	Should we be imaging lymph nodes at initial diagnosis of earlyâ€stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*. British Journal of Dermatology, 2021, 184, 524-531.	1.5	18
114	Differential expression of <scp>TOX</scp> by skinâ€infiltrating T cells in SÃ©zary syndrome and erythrodermic dermatitis. Journal of Cutaneous Pathology, 2015, 42, 604-609.	1.3	17
115	The Mutational Landscape of CTCL and Sezary Syndrome. Blood, 2015, 126, 573-573.	1.4	17
116	Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management. Dermatology and Therapy, 2022, 12, 29-40.	3.0	17
117	Mouse fingers, a new computer-related skin disorder. Journal of the American Academy of Dermatology, 2001, 45, 477.	1.2	16
118	Antiplectin autoantibodies in subepidermal blistering diseases. British Journal of Dermatology, 2009, 161, 762-771.	1.5	16
119	A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology, 2017, 27, 286-294.	0.6	16
120	A Delayed Granulomatous Reaction to a Cosmetic Tattoo of the Eyebrows: A Report of Total Regression After Intralesional Corticosteroid Injections. Dermatologic Surgery, 2012, 38, 951-953.	0.8	15
121	Incidence of mycosis fungoides and SÃ©zary syndrome in the Netherlands between 2000 and 2020. British Journal of Dermatology, 2021, 185, 434-435.	1.5	15
122	Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study. Blood, 2017, 130, 817-817.	1.4	15
123	Wholeâ€genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm. Genes Chromosomes and Cancer, 2020, 59, 295-308.	2.8	14
124	Management of primary cutaneous lymphoma patients during COVIDâ€19 pandemic: EORTC CLTF guidelines. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1633-1636.	2.4	14
125	Recent advances in primary cutaneous B-cell lymphomas. Current Opinion in Oncology, 2014, 26, 230-236.	2.4	13
126	A novel keratin 13 variant in a fourâ€generation family with white sponge nevus. Clinical Case Reports (discontinued), 2017, 5, 1503-1509.	0.5	12

#	Article	IF	Citations
127	Folliculotropic mycosis fungoides presenting with a solitary lesion: Clinicopathological features and longâ€term followâ€up data in a series of 9 cases. Journal of Cutaneous Pathology, 2018, 45, 122-128.	1.3	12
128	Acquired N-Linked Glycosylation Motifs in B-Cell Receptors of Primary Cutaneous B-Cell Lymphoma and the Normal B-Cell Repertoire. Journal of Investigative Dermatology, 2019, 139, 2195-2203.	0.7	12
129	Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in SÃ©zary cells. Biochemistry and Biophysics Reports, 2020, 24, 100832.	1.3	12
130	The importance of assessing blood tumour burden in cutaneous Tâ€cell lymphoma*. British Journal of Dermatology, 2021, 185, 19-25.	1.5	12
131	Primary cutaneous peripheral Tâ€cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinicoâ€pathological and prognostic features. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 658-668.	2.4	12
132	Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 667-675.	2.8	12
133	A restricted clonal T-cell receptor Î±Î² repertoire in SÃ©zary syndrome is indicative of superantigenic stimulation. British Journal of Dermatology, 2011, 165, 78-84.	1.5	11
134	Arrayâ€based CGH of primary cutaneous CD8+ aggressive EPIDERMOâ€tropic cytotoxic Tâ€cell lymphoma. Genes Chromosomes and Cancer, 2018, 57, 622-629.	2.8	11
135	Remission of psoriasis during treatment with sorafenib. JAAD Case Reports, 2018, 4, 1065-1067.	0.8	10
136	Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome. European Journal of Cancer, 2018, 101, 278-280.	2.8	10
137	Score test for association between recurrent events and a terminal event. Statistics in Medicine, 2016, 35, 3037-3048.	1.6	9
138	Outcomes of rare patients with a primary cutaneous CD30+ lymphoproliferative disorder developing extracutaneous disease. Blood, 2020, 135, 769-773.	1.4	9
139	Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma. Haematologica, 2022, 107, 1619-1632.	3.5	9
140	Bullous systemic lupus erythematosus responding to mycophenolate mofetil. European Journal of Dermatology, 2010, 20, 844-5.	0.6	9
141	Flow cytometry for the assessment of blood tumour burden in cutaneous Tâ€cell lymphoma: towards a standardized approach. British Journal of Dermatology, 2022, 187, 21-28.	1.5	9
142	Annular erythema of SjÃ¶gren's syndrome. Lancet, The, 2006, 367, 1604.	13.7	8
143	Loss of the GPIâ€anchor in Bâ€lymphoblastic leukemia by epigenetic downregulation of PIGH expression. American Journal of Hematology, 2019, 94, 93-102.	4.1	8
144	Pitfalls in diagnosing primary cutaneous aggressive epidermotropic <scp>CD</scp> 8 ⁺ Tâ€cell lymphoma. British Journal of Dermatology, 2019, 180, 411-412.	1.5	8

#	Article	IF	Citations
145	Increased Expression of PLS3 Correlates with Better Outcome in SÃ©zary Syndrome. Journal of Investigative Dermatology, 2017, 137, 754-757.	0.7	7
146	Should primary cutaneous Ki-1(CD30)-positive anaplastic large cell lymphoma in childhood be treated with multiple-agent chemotherapy?. Journal of the American Academy of Dermatology, 2001, 45, 638-639.	1.2	6
147	Microarray Techniques to Analyze Copy-Number Alterations in Genomic DNA: Array Comparative Genomic Hybridization and Single-Nucleotide Polymorphism Array. Journal of Investigative Dermatology, 2015, 135, 1-5.	0.7	6
148	Micro RNA â€155 potentiates tumour development in mycosis fungoides. British Journal of Dermatology, 2017, 177, 618-620.	1.5	6
149	The clinical spectrum of mycosis fungoides in Tanzania, East Africa. British Journal of Dermatology, 2017, 176, 1653-1656.	1.5	6
150	Generalized Molluscum Contagiosum Successfully Treated with Interferon-Alpha in a Patient with Folliculotropic Mycosis Fungoides. Case Reports in Dermatology, 2019, 11, 52-56.	0.8	6
151	Botulinum toxin type A in the treatment of Raynaud's phenomenon. Dermatologic Therapy, 2020, 33, e14182.	1.7	6
152	First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results. Blood, 2016, 128, 1826-1826.	1.4	6
153	EPHA4 is overexpressed but not functionally active in SÃ©zary syndrome. Oncotarget, 2015, 6, 31868-31876.	1.8	6
154	Coincidence of cutaneous follicle center lymphoma and diffuse large Bâ€cell lymphoma. International Journal of Dermatology, 2008, 47, 21-24.	1.0	5
155	Quantitation of tumour development correlates with prognosis in tumour stage (stage IIB) mycosis fungoides. British Journal of Dermatology, 2014, 170, 1080-1086.	1.5	5
156	Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial. European Journal of Cancer, 2021, 156, S46.	2.8	5
157	Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial. Blood, 2020, 136, 23-24.	1.4	5
158	Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas. Archives of Dermatology, 2001, 137, 901-5.	1.4	5
159	Mutation in PIGA Results in a CD52-Negative Escape Variant in a SÃ©zary Syndrome Patient during Alemtuzumab Treatment. Journal of Investigative Dermatology, 2015, 135, 1199-1202.	0.7	4
160	Antibiotics can improve CTCL. Blood, 2019, 134, 1000-1001.	1.4	4
161	Corresponding anaplastic lymphoma kinaseâ€“tropomyosin 3 (ALK-TPM3) fusion in a patient with a primary cutaneous anaplastic large-cell lymphoma and a Spitz nevus. JAAD Case Reports, 2019, 5, 970-972.	0.8	4
162	Epidemiology of cutaneous lymphoma. British Journal of Dermatology, 2021, 184, 993-994.	1.5	4

#	Article	IF	Citations
163	Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis.. Journal of Clinical Oncology, 2019, 37, 7539-7539.	1.6	4
164	516 Global collaboration for establishment of a prognostic index in mycosis fungoides & Sezary Syndrome. Journal of Investigative Dermatology, 2018, 138, S88.	0.7	3
165	IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study. European Journal of Cancer, 2018, 101, S29.	2.8	3
166	A rare case of cutaneous Epstein-Barr virusâ€“negative intravascular cytotoxic T-cell lymphoma. JAAD Case Reports, 2019, 5, 548-551.	0.8	3
167	TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED CUTANEOUS T-CELL LYMPHOMA (CTCL) RECEIVING MOGAMULIZUMAB OR VORINOSTAT: A POST-HOC ANALYSIS OF THE MAVORIC STUDY. Hematological Oncology, 2019, 37, 285-286.	1.7	3
168	Safety of Mogamulizumab in Mycosis Fungoides and SÃ©zary Syndrome: Final Results from the Phase 3 Mavoric Study. Blood, 2019, 134, 5300-5300.	1.4	3
169	Primary Cutaneous Follicle Center Lymphomas (PCFCL) Express Heavily Mutated B-Cell Receptors with Acquired N-Glycosylation Motifs and Lack Ongoing Somatic Hypermutation. Blood, 2018, 132, 1573-1573.	1.4	3
170	Total skin electron beam therapy for cutaneous T-cell lymphomas in the Netherlands: A retrospective analysis of treatment outcomes and selection for high or low dose schedule. Clinical and Translational Radiation Oncology, 2022, 33, 77-82.	1.7	3
171	Carcinoma erysipeloides in breast cancer. Surgery, 2010, 148, 1040-1041.	1.9	2
172	Special variant of histiocytosis. BMJ Case Reports, 2017, 2017, bcr-2017-221538.	0.5	2
173	Serum and cutaneous transcriptional expression levels of IL31 are minimal in cutaneous T cell lymphoma variants. Biochemistry and Biophysics Reports, 2021, 26, 101007.	1.3	2
174	IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial. Blood, 2018, 132, 684-684.	1.4	2
175	A Cutaneous Lymphoma International Consortium â€˜CLICâ€™ study of Prognostic Parameters in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Progress Towards Establishing a Prognostic Index to Augment Clinical Staging. Blood, 2014, 124, 1621-1621.	1.4	2
176	Erythematous and purpuric plaques of the face and scalp in Sweet syndrome. British Journal of Haematology, 2011, 154, 159-159.	2.5	1
177	Major achievements of the EORTC Cutaneous Lymphoma Task Force (CLTF). European Journal of Cancer, Supplement, 2012, 10, 46-50.	2.2	1
178	Classification and recommended treatment options for folliculotropic mycosis fungoides. Expert Opinion on Orphan Drugs, 2018, 6, 35-45.	0.8	1
179	Levels of IL-31 in different variants of cutaneous T cell lymphomas. European Journal of Cancer, 2018, 101, S17.	2.8	1
180	Prognostic factors in mycosis fungoides: the PROCLIPI study. European Journal of Cancer, 2019, 119, S26.	2.8	1

#	Article	IF	Citations
181	Abstract LB-012: Autonomous, antigen-independent B-cell receptor signalling as a novel pathogenetic mechanism in non-GCB DLBCL. , 2016, , .		1
182	Antigen-Independent, Autonomous B-Cell Receptor Signaling As a Dominant Candidate Oncogenic Mechanism in ABC DLBCL. Blood, 2016, 128, 778-778.	1.4	1
183	Sentinel node biopsy in cutaneous melanoma patients with germline CDKN2A mutations. Melanoma Research, 2020, 30, 630-631.	1.2	1
184	Mass Cytometric Analysis of Early-Stage Mycosis Fungoides. Cells, 2022, 11, 1062.	4.1	1
185	Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers, 2022, 14, 1510.	3.7	1
186	Progression of mycosis fungoides is associated with expression of granzyme B and TIA-1 in neoplastic cells. Journal of Dermatological Science, 1998, 16, S53.	1.9	0
187	Limited effect of chemotherapy in cutaneous lymphoma. Blood, 2015, 125, 4-5.	1.4	0
188	183 Cutaneous lymphoma international consortium (CLIC): Uniting worldwide experts to develop and validate a prognostic index model. Journal of Investigative Dermatology, 2016, 136, S32.	0.7	0
189	Lymph node imaging in patch/plaque mycosis fungoides; enlarged LN are infrequent but lymphomatous nodal involvement may occur and upstage patients to advanced disease. European Journal of Cancer, 2018, 101, S25-S26.	2.8	0
190	Genomic analysis reveals recurrent deletion of HNRNPK and SOCS1 in mycosis fungoides. European Journal of Cancer, 2018, 101, S7.	2.8	0
191	Treatment of early-stage mycosis fungoides: Results from the PROCLIPI study. European Journal of Cancer, 2018, 101, S34.	2.8	0
192	The PROCLIPI study; a prototype registry for rare disease with global collaboration for establishment of a prognostic index in mycosis fungoides and Sezary syndrome. European Journal of Cancer, 2018, 101, S6.	2.8	0
193	Frequency of associated haematologic malignancies in lymphomatoid papulosis: A preliminary report of 505 patients from the Dutch Cutaneous Lymphoma Group. European Journal of Cancer, 2018, 101, S6.	2.8	0
194	Standardized flow cytometry (EuroFlow) demonstrates heterogeneous T-cell origin of SÃ©zary lymphoma cells. European Journal of Cancer, 2018, 101, S8.	2.8	0
195	Cell adhesion molecule 1 (CADM1) can be a biomarker for SÃ©zary syndrome. European Journal of Cancer, 2019, 119, S7.	2.8	0
196	Treatment of rare patients with a primary cutaneous CD30+ lymphoproliferation developing extracutaneous disease: a retrospective study of 43 patients. European Journal of Cancer, 2019, 119, S28-S29.	2.8	0
197	PD-1 overexpression in SÃ©zary syndrome is epigenetically regulated. European Journal of Cancer, 2019, 119, S2.	2.8	0
198	Molecular analysis of primary cutaneous diffuse large B-cell lymphoma, leg type at diagnosis and relapse. European Journal of Cancer, 2019, 119, S8-S9.	2.8	0

#	Article	IF	Citations
199	Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm. European Journal of Cancer, 2019, 119, S9.	2.8	0
200	Clinical, histological and molecular characteristics of ALK-positive primary cutaneous anaplastic large cell lymphoma. European Journal of Cancer, 2019, 119, S18.	2.8	0
201	Treatment of early-phase mycosis fungoides: results from the Prospective Cutaneous Lymphoma International (PROCLIPI) study. European Journal of Cancer, 2019, 119, S27.	2.8	0
202	Time to Next Treatment in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL) Receiving Mogamulizumab or Vorinostat: A MAVORIC Post-Hoc Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S361.	0.4	0
203	T-cell receptor rearrangements in the skin and blood of patients in the PROCLIPI study: detection of clonal rearrangements in the skin (and blood) correlates with the B-class of MF and SS patients. European Journal of Cancer, 2019, 119, S25.	2.8	0
204	Human papillomavirus 16â€“positive supraclavicular cutaneous squamous cell carcinoma metastatic to the level IV supraclavicular lymph nodes. JAAD Case Reports, 2020, 6, 822-825.	0.8	0
205	A baby with red plaques on the face and a first-degree heart block: neonatal lupus. Lancet, The, 2020, 396, 1432.	13.7	0
206	First Line Treatment of Aggressive Cutaneous NK/T Cell Lymphomas Based on High Dose Cytarabine and Stem Cell Transplantation Does Not Lead to Durable Remissions.. Blood, 2006, 108, 4669-4669.	1.4	0
207	Genome Wide Analysis of 41 Mycosis Fungoides Tumor Stage Using Array Comparative Genomic Hybridization Technology.. Blood, 2008, 112, 1769-1769.	1.4	0
208	The EORTC Cutaneous T-Cell Lymphoma (CTCL) Platform. Blood, 2010, 116, 4896-4896.	1.4	0
209	Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control. Blood, 2011, 118, 2491-2491.	1.4	0
210	Loss of Pigh Expression Frequently Results in a GPI-Negative Subclone Lacking CD52 Membrane Expression, Conferring Alemtuzumab Resistance to B Cell Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1435-1435.	1.4	0
211	First-in-human, open label, multicenter phase I of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas.. Journal of Clinical Oncology, 2016, 34, TPS2591-TPS2591.	1.6	0
212	The B-Cell Receptor of Primary Cutaneous Follicle Center Lymphoma: Implications for Pathogenesis. Blood, 2016, 128, 4136-4136.	1.4	0
213	Tumor Clone Frequency Calculation Using High-Throughput Sequencing of the TCRÎ² Gene in Patients with Folliculotropic Mycosis Fungoides. Journal of Investigative Dermatology, 2022, 142, 2544-2546.e2.	0.7	0